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Abstract
Background and purpose: The aim of this study was to test
the hypothesis that polymorphisms of the paraoxonase genes
PON1 and PON2 may be associated with increased risk of
developing multiple sclerosis (MS) in the Polish population.
Material and methods: We studied the significance of the
PON gene polymorphisms C311S, A162G, Q192R and
L55M in 221 patients (including 145 women) with MS and
in 661 healthy controls. In the MS population, mean Expand-
ed Disability Status Scale score was 2.92, mean age was 
36.8 years, and mean disease duration was 7.7 years. PON
ge notyping was determined using polymerase chain reaction
and restriction enzyme digestion.
Results: According to our results, the PON1 and PON2
genotypes distribution did not differ between the MS patients
and the controls.
Conclusions: The polymorphisms of the PON genes studied
are not related to increased risk of MS in the Polish popula-
tion.
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SHORT REPORT/KRÓTKIE DONIESIENIE
St reszc zen ie
Wstêp i cel pracy: Celem pracy by³o zweryfikowanie hipote-
zy, ¿e polimorfizm genów PON1 i PON2mo¿e byæ zwi¹zany
z ryzykiem wyst¹pienia stwardnienia rozsianego (SR) w popu-
lacji polskiej.
Materia³ i metody: Autorzy badali znaczenie polimorfizmu
genów PON: C311S, A162G, Q192R oraz L55M, u 221 cho-
rych na SR (w tym 145 kobiet) oraz u 661 zdrowych osób z gru-
py kontrolnej. W grupie chorych na SR œrednia punktacja
w Expanded Disability Status Scale (EDSS) wynosi³a 2,92 pkt,
œrednia wieku – 36,8 roku, a œredni czas trwania choroby – 
7,7 roku. Polimorfizm –A162G genu PON1 badano za pomoc¹
reakcji ³añcuchowej polimerazy (PCR) z analiz¹ iloœci produktu
w czasie rzeczywistym, a pozosta³e polimorfizmy za pomoc¹
PCR i trawienia odpowiednimi enzymami restrykcyjnymi.
Wyniki: Nie stwierdzono istotnych statystycznie ró¿nic w roz-
 k³adzie genotypów PON1 i PON2 pomiêdzy grup¹ chorych
a grup¹ kontroln¹.
Wnioski: Wyniki pracy nie wskazuj¹, aby istnia³a zale¿noœæ
pomiêdzy polimorfizmem genów PON1 oraz PON2 a zwiê k -
szonym ryzykiem wyst¹pienia SR w populacji polskiej.
S³owa kluczowe: stwardnienie rozsiane, PON1, PON2, poli-
morfizm.
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Introduction
Multiple sclerosis (MS) is a chronic degenerative
disease of the central nervous system (CNS) that is char-
acterised by inflammation, myelin loss, oligodendrocyte
depletion, gliosis and axonal pathology. The aetiology of
MS is not known, but includes both genetic and envi-
ronmental factors [1]. Increasing evidence supports the
role of oxidative stress and free radicals in the patho-
genesis of MS. The CNS is characterised by high oxy-
gen consumption as well as a high level of polyunsatu-
rated fatty acid (PUFA), making it especially vulnerable
to lipid peroxidation. Increased lipid peroxide levels have
been reported in the cerebrospinal fluid (CSF) and in
the blood of MS patients [2].
High density lipoproteins (HDL) are involved in
the antioxidant effect against lipid peroxidation induced
by free radicals. The protective effect of HDL against
lipid peroxidation seems to be related to HDL surface
proteins – paraoxonases (PON). Paraoxonase-1 (PON1)
is encoded by the gene PON1 on chromosome 7q21.3
and is expressed in a variety of tissues but is mainly syn-
thesized by the liver [3,4]. PON1 is a calcium-depen-
dent esterase first described for its capacity to hydrolyse
organophosphates but now considered more important
for its antioxidative and anti-inflammatory properties
such as low-density lipoprotein (LDL) protection
against oxidative stress, reduction of macrophage foam
cell formation and prevention of atherosclerosis devel-
opment [4]. The high variability in PON1 activity has
been attributed to gene polymorphism, which has been
associated with various diseases: coronary heart disease,
Parkinson disease or diabetes mellitus type 2 (for review
see [4]). There are two major PON1 gene polymor-
phisms, Q192R and L55M, which independently mod-
ify activity of plasma paraoxonase. Alleles R and L of
PON1 are associated with decreased ability of the
enzyme to protect LDL against oxidation [4].
Next to the PON1 gene on chromosome 7 is the
locus for PON2, whose mRNA has been detected in
almost every human tissue but whose product and func-
tion are still not fully known. PON2 is not present in
HDL particles in the circulation. It has been suggest-
ed that PON2 is responsible for reduction of oxidative
stress and protection against atherosclerosis [3]. PON2
gene polymorphism has been described in a number of
disorders: cardiovascular, diabetes mellitus type 2 and
inflammatory bowel diseases (for review see [4]). An
example may be allele C of PON2, which causes lower
ability to protect LDL as compared to allele S [3].
The decreased antioxidative activity of paraoxonase,
seen in carriers of PON1 alleles R and L, as well as
weakening of the local antioxidant mechanisms in PON2
allele C carriers may be associated with an increased risk
of developing MS. To identify genetic factors of increas-
ing MS risk, we mapped the most common polymor-
phisms of genes PON1 and PON2 (C311S, A162G,
Q192R and L55M) in Polish patients with MS and in
healthy controls.
Material and methods
We studied 221 unrelated patients with clinically def-
inite MS diagnosed according to the McDonald criteria
[5] from MS Units in Departments of Neurology from
Krakow and Warsaw (145 women and 76 men; mean age
36.8 ± 10.5 yrs; mean disease duration 7.70 ± 6.8 yrs;
mean disease onset 28.8 ± 9.1 yrs, mean Expanded Dis-
ability Status Scale [EDSS] score 2.92 ± 2.0 points).
The course of MS was relapsing-remitting (RR) in 
155 pa tients (70.14%), progressive-relapsing (RP) in 
22 (9.95%), primary progressive (PP) in 2 (0.91%) and
secondary progressive (SP) in 42 (9.95%). We compared
the results with the control group (n = 661; 335 women;
mean age 55.3 ± 17.3 yrs). MS patients were signifi-
cantly younger than the controls (p< 0.01) and the gen-
der distribution was unequal (65.5% women in MS group
vs. 55.7% in control group) (p< 0.002). All control sub-
jects had no history of previous neurological diseases and
were examined by neurologists to exclude neurological
disorders. Both patients and controls were of Caucasian
origin and Polish descent. All participants gave informed
consent prior to inclusion in the study. The protocol was
reviewed and approved by the Ethics Committee of the
Jagiellonian University in Krakow.
DNA analyses
The PON1Q192R (rs 662), L55M (rs 854560), –
161 C/T (rs 705381) and PON2 C311S (rs 6954345)
polymorphisms were studied. DNA was extracted from
leucocytes using a commercially available kit (Boehrin -
ger Mannheim, Germany).
The individual genotypes for the PON1Q192R and
PON1 L55M single nucleotide polymorphisms (SNPs)
were determined using the polymerase chain reaction
restriction fragment length polymorphism method [6].
The PON2 C311S genotyping was determined using
polymerase chain reaction and restriction enzyme diges-
tion [7].
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Genotyping of the –161 C/T PON1 polymorphism
was performed on an ABI PRISM® 7900 HT Fast
Real-Time PCR System (Applied Biosystems) using
TaqMan Universal PCR Master Mix (Applied Biosys-
tems) as described elsewhere [8].
Statistical analyses
The genotype and allele frequencies of the PON SNPs
were compared between cases and controls using the χ2
test (SAS Genetics 9.1). The Hardy-Weinberg equilibri-
um was verified for all polymorphisms in the tested pop-
ulation. Adjusted odds ratios (OR) with 95% confidence
intervals (CI) were estimated by logistic regression, con-
trolling for age and gender. Because four different poly-
morphisms were assessed, the Bonferroni correction was
applied and the level of significance was set at p < 0.01.
Results
The genotypes and allele frequencies were in Hardy-
Weinberg equilibrium for both groups. Genotypes and
allele frequencies did not differ significantly between
MS patients and the control group and were not influ-
enced by gender and age (Table 1).
Discussion
Until now only a few studies have been conducted
considering the role of oxidative stress, especially lipid
oxidation, in the pathogenesis of MS. Newcombe et al.
[9] reported the presence of oxidated LDL and lipid
oxidation products in early and active demyelinating
plaques in brain biopsy specimens from MS patients.
Besler et al. [10] reported a significantly higher index
of plasma oxidation, higher anti-oxLDL antibody lev-
el as well as marked decrease of plasma antioxidative
activity in MS patients in comparison to healthy con-
trols. The presence of oxidative damage to proteins,
lipids and nucleotides as well as marked upregulation of
antioxidant enzymes has also been shown in active
demyelinating lesions (for review see [2]). Ferreti et al.
[11] reported that MS patients in the early stage of 
disability (EDSS < 3.5) have lower activity of plasma
MS patients Control group p-value p-value
(n = 221) (n = 661)
PON1 Q192R Genotypes
QQ 112 (50.7%) 364 (55.1%) 0.26* 0.19**
QR 95 (43.0%) 253 (38.1%) 0.87# 0.81##
RR 14 (6.3%) 44 (6.65%) 0.396§ 0.25§§
L55M Genotypes
LL 96 (43.4%) 274 (41.5%) 0.60* 0.39**
LM 100 (45.3%) 320 (48.4%) 0.62# 0.87##
MM 25 (11.3%) 67 (10.1%) 0.87§ 0.47§§
A162G Genotypes
GG 117 (52.9%) 372 (56.3%) 0.39* 0.53**
GA 92 (41.6%) 250 (37.8%) 0.82# 0.51##
AA 12 (5.4%) 39 (5.9%) 0.54§ 0.44§§
PON2 C311S Genotypes
SS 131 (59.3%) 392 (59.3%) 0.99* 0.91**
SC 76 (34.4%) 226 (34.2%) 0.93# 0.47##
CC 14 (6.3%) 43 (6.5%) 0.98§ 0.71§§
Table 1. Distribution of genotypes of PON1 and PON2 gene polymorphisms in Polish multiple sclerosis (MS) patients and in control group
*dominant model (RR + QR vs. QQ); logistic regression analysis
**dominant model (RR + QR vs. QQ); logistic regression analysis after adjustment for age and sex
#recessive model (QQ + QR vs. RR); logistic regression analysis
##recessive model (QQ + QR vs. RR); logistic regression analysis after adjustment for age and sex
§additive model (RR vs. QR vs. QQ); the Cochran-Armitage trend test
§§additive model (RR vs. QR vs. QQ) after adjustment for age and gender (the Cochran-Armitage trend test)
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paraoxonase and about 5-fold higher level of cholesteryl
ester hydroperoxides (CE-OOH) (marker of lipid per-
oxidation) as compared to healthy controls. In another
study published in 2006 [12], they suggested increased
spontaneous intracellular production of free radicals in
leucocytes of MS patients compared to healthy controls.
Moreover, Ferreti et al. [12] found a positive correla-
tion between increased free radical production and
EDSS score, magnetic resonance imaging changes and
visual evoked potential results. Sidoti et al. [13] report-
ed increased risk of developing MS among Italian
patients with PON55/LM-MM genotype compared
with other genotypes. However, the results of a study by
Martinez et al. [14] were controversial. They found that
the frequencies of the PON1 genotypes and allelic vari-
ants did not differ between MS patients and healthy con-
trols in the Spanish Caucasian population and were
unrelated to gender, age of onset and MS course.
In our study, we did not find any significant dif-
ferences in the PON1 (Q192R, L55M, A162G) and
PON2 C311S genotypes and allele distribution between
Polish patients with MS and the control group.
Our study has some obvious limitations. MS patients
and controls were not sex-matched. This is mainly due
to the fact of higher prevalence of MS among women
(with a female to male ratio of 2 : 1), while the control
group was population based. The stratified analysis by
gender showed no differences between females and
males and therefore the lack of gender matching seemed
to be irrelevant. Our MS group was also significantly
younger than the controls, but statistical stratified analy-
sis showed no influence of age.
Conclusion
The results of the present study suggest that PON1
and PON2 polymorphisms are not a risk factor of devel-
oping MS in the Polish population.
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